21 May 04
To aid in your drug development efforts, Pharmaceutical Education Associates is proud to present our inaugural “Identification and Validation of Safety and Efficacy Biomarkers” conference. Ultimately, the drug discovery process must be a collaborative one, drawing together researchers from industry, academia, and government agencies to identify and address all possible benefits and consequences. In that spirit, our top-notch speaking faculty brings together experts from all these groups to add
20 May 04
DailyUpdates 20th April: Nearly 423,000 new cases of small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC) are expected to have been diagnosed in the seven major pharmaceutical markets in 2003. Despite the high level of pharmaceutical interest, there are significant unmet needs in the disease in terms of poor survival. Docetaxel is the only drug currently approved in both the U.S. and Europe to treat patients with non-small cell lung cancer in the second-line setting. While the dr
11 May 04
DailyUpdates 11th May: A number of clinical studies including the VIGOR trial have suggested that the NSAID naproxen may reduce the incidence of myocardial infarction. However the gastrointestinal side-effects of naproxen and its ability to exacerbate hypertension preclude its use in at-risk individuals. Upcoming data about to be published in the journal JPET demonstrate the efficacy of the safer and anti-hypertensive nitro-derivative of naproxen, HCT 3012, in a model of myocardial infarction.
10 May 04
DailyUpdates 10th May: Last week European regulators affirmed the safety of Celebrex; good news for Pfizer continues with the emergence of data from the PACES trials reporting that, compared to acetaminophen, Celebrex is both preferred by patients and is of greater efficacy.
07 May 04
Learn innovative ways to analyze data derived from signals in clinical development as well as post-maketing surveillance.
06 May 04
This edition of Emerging Drug Discovery Targets features MBD2 inhibitors as a selective strategy for reducing tumor growth; NicOx's NO-ASA cancer candidate, NCX 4040, MIF as a target for atherogenesis; expanding indications for COX-2 inhibitors; and a dual MMP and TACE inhibitor as a treatment of rheumatoid arthritis. This edition also sees a new section "TherapyUpdate" which this month focuses on Osteoporosis. As usual we also provide updates on industrial advances and licensing opportunities a
05 May 04
DailyUpdates 5th May: As the battle lines are drawn up between gabapentin and its generic equivalents, research published by Turkish researchers suggests that the first-line use of these therapeutics in the treatment of neuropathic pain associated with spinal cord injury will represent one battle in the war between Pfizer and its competitors.
29 Apr 04
DailyUpdates 29th April: Cancer pain affects over 3 million people in the US alone. The treatment of this condition, whether it is due to bone metastasis or a result of the use of cytotoxic therapies is challenging. Researchers from McGill University have now demonstrated that ethosuximide, an anti-epileptic and relatively selective T-type calcium channel blocker, is highly effective in reversing neuropathic pain caused by the commonly employed cytotoxics paclitaxel or vincristine. This contr
PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.